| INTRODUC TI ON
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder of the central nervous system (dos Santos et al., 2018) . AD is pathologically characterized by extracellular deposition of fibrillar amyloid-β (Aβ) and hyperphosphorylation of tau with subsequent intraneuronal formation of neurofibrillary tangles (Villemagne et al., 2013) .
Clinically, these changes are accompanied by progressive memory loss and cognitive decline (Shepherd et al., 2019) . Aβ is generated by the sequential processing of the amyloid precursor protein by two aspartyl proteases: the β-and γ-secretases (Busciglio, Gabuzda, Matsudaira, & Yankner, 1993; Cai, Golde, & Younkin, 1993; Haass, Koo, Mellon, Hung, & Selkoe, 1992) . Under normal conditions, Aβ peptides are removed from the brain through local degradation and by transfer into both the cerebrospinal fluid and blood vessels (Heneka, Golenbock, & Latz, 2015b) . Previously it has been shown that fibrillar Aβ can activate the same immune receptors that respond to pathogen-associated molecular patterns including viral proteins or bacterial lipopolysaccharides (LPS) , thereby contributing to the neuroinflammatory component of AD (Heneka, Carson, et al., 2015a) .
Less clear however, is whether other Aβ species such as protofibrils or oligomers are able to initiate a similar immune reaction and which inflammatory downstream signalling cascades are involved.
Fibrillar Aβ can initiate a neuroinflammatory immune response through activation of the NOD-like receptor (NLR) family, pyrin domain-containing 3 (NLRP3) inflammasome (Heneka et al., 2013) .
The NLRP3 inflammasome, in addition to the NLRP3 protein, also includes apoptosis-associated speck-like protein (ASC) and procaspase-1 (Ito et al., 2015; Shao, Xu, Han, Su, & Liu, 2015) . Activation of the NLRP3 inflammasome leads to caspase-1 activity and consequently to the release of pro-inflammatory cytokines, such as interleukin-1β (IL-1β) and interleukin-18 (IL-18) (Shao et al., 2015) .
Thus far, conflicting data exist regarding Aβ's ability to induce a pro-inflammatory cytokine response (Maezawa, Zimin, Wulff, & Jin, 2011) . One possible reason for this could be that the wide range of Aβ aggregates studied had different structures and origin, including those that were chemically synthesized or recombinant peptides. It has also been argued that some of the Aβ preparations used may have been contaminated with LPS, which could (at least partly) account for the observed inflammatory response. Importantly, the different physical and biochemical properties of Aβ may lead to diverse cellular reactions including differences in microglia activation (Ferrera, Mazzaro, Canale, & Gasparini, 2014; Lindberg, Selenica, Westlind-Danielsson, & Schultzberg, 2005) .
Fibrillar Aβ induces NLRP3 inflammasome activation in microglia (Halle et al., 2008) , but it remains unclear whether small Aβ oligomers and protofibrils, that seem to be more neurotoxic (Cizas et al., 2010; Umeda et al., 2011; Yang, Li, Xu, Walsh, & Selkoe, 2017) , similarly activate the NLRP3 inflammasome in microglia. Therefore, we selected soluble Aβ oligomers and protofibrils, with proven neurotoxicity (Deleglise et al., 2014; Fixman et al., 2017; Herzer, Meldner, Rehder, Gröne, & Nordström, 2016; Porter et al., 2016; Shin et al., 2014) , to examine their ability to activate the microglial NLRP3 inflammasome by assessing caspase-1 activation, IL-1β release and ASC speck formation. For this experiment, mice were housed for primary microglia cell preparation only which did not require further approval. For microglia isolation, the brains of 221 0-3-day-old pups were used. The pups were killed by decapitation without anaesthesia. Primary microglia were isolated as described before with some adaptations (Giulian & Baker, 1986) . Briefly, brains from neonatal (p0-p2, mixed gender cultures) C57BL/6 (WT) (purchased from Charles River Laboratories Inc., RRID: IMSR_JAX:000,664) mice were stripped of the meninges and dissociated using mechanical shearing and trypsin. Cells of two brains were plated on PLL-coated T75 culture flasks (Greiner Bio-One) and cultivated in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin. On the next day, cells were washed three times with PBS to remove cellular debris and cultured with DMEM supplemented with 10% FBS, 1% P/S and 10% L929 conditioned medium as a source of growth factors. After approximately 8 days, loosely attached mature microglia were shaken off the astrocytic monolayer with a repetition of the harvesting procedure at every 2-3 days for up to three times. Cells were seeded at a density of 1 million/cm 2 in 1/2 old medium (condition medium from microglia shake) and 1/2 fresh DMEM supplemented with 10% FBS and 1% P/S and allowed to adhere overnight. On the next day, microglia were primed with 50 ng/ml LPS for 3 hr and treated with 2.5 μM Aβ aggregates for 6 hr in a serum-free DMEM containing 1% P/S. As a positive control, the inflammasome inducer nigericin was used at 10 μM concentration. MCC950, which selectively inhibits the NLRP3 inflammasome, was used at 1 μM concentration. These in vitro protocols are used on a daily basis in the laboratory; therefore, we have not performed preliminary sample calculation. No blinding was applied in the cell culture treatment.
| MATERIAL S AND ME THODS

| Materials
| Cell culture
| Aβ preparation
Aβ oligomers and protofibrils were prepared according to the protocol of Stine (Stine, Dahlgren, Krafft, & LaDu, 2003) . Briefly, Aβ was dissolved in ice cold HFIP to a final concentration of 221 μM. About 100 μl aliquots were incubated at 20°C for 1 hr and centrifuged in a speed vacuum centrifuge at 800 × g for 10 min until the HFIP had evaporated. The tubes with the peptide film were stored at −80°C. Aβ pre-treated with HFIP and was dissolved in DMSO to a final concentration of 2.5 mM and sonicated for 10 min. Aβ or the DMSO vehicle control was added to phenol red-free DMEM to a final concentration of 100 μM and incubated for 24 hr at 4 or 37°C. To confirm that the Aβ oligomers and protofibrils were intact during cell culture treatment further analysis was performed. Aβ preparations were diluted with DMEM from 10 to 2.5 μM and incubated for 6 hr at 37°C and 5% CO 2 to produce oligomers (Protocol I) and protofibrils (Protocol II), respectively. Aβ oligomers and protofibrils were then characterized by AFM.
The buffers used for the preparation of Aβ served as controls for all cell culture experiments with Aβ oligomers or protofibrils. They are referred as oligomers control (Con. O) or protofibrils control (Con. P).
| Atomic force microscopy imaging
To assess the size and morphology of the Aβ oligomers and protofibrils, AFM measurements were performed using a Dimension Icon system (Bruker) in tapping mode in air. Imaging was performed at 20°C using TESP-V2 cantilevers with a nominal spring constant 40 N/m. Freshly cleaved mica sheets (grade 4, SPI Supplies) were modified with PLL for 10 min, and then rinsed with deionized water, and dried under a nitrogen stream. Before measurement 20 μL of a 2.5 μM Aβ solution was spotted on modified mica surface for 10 min, and then rinsed with deionized water, and dried under nitrogen stream. Images were acquired at scan rate 0.4 Hz in 512 × 512 pixel mode. Images were analysed by v4.0 Beta 9.1 WSxM (Horcas et al. 2007 ) and Nanoscope Analysis v1.40 (Bruker) software. The mean height of Aβ oligomers and protofibrils ("zheight") was estimated by determining step-height histograms.
| Cell viability/cytotoxicity assay
Cell viability/cytotoxicity was measured using three different assays:
LDH release, XTT assay and PI/Hoechst nuclear staining.
To assess the cytotoxicity of Aβ, an LDH cytotoxicity detection kit was used. A quantity of 50 μL of cell supernatants was used to perform the cytotoxicity assay according to the manufacturer's protocol. Absorbance was measured at 450 nm using a microplate reader.
The metabolic activity of primary microglia was quantified using the XTT Cell Viability Kit. Primary microglia were seeded at 1 million cell/ml into 96-well plates and treated with 100 μl medium per well. After treatment with the various stimuli, the XTT Reagent and Electron Coupling Solution were added directly to the cell culture medium according to the manufacturer's protocol and incubated for 4 hr. Absorbance was measured at 450 nm with a microplate reader.
To determine cell viability PI/Hoechst nuclear staining was used.
Nuclei were stained with 1.25 μg/ml PI and 1 μg/ml Hoechst33342 in cell culture medium for 30 min. The cells were washed with PBS and fixed with 4% PFA. The fluorescent signal was determined using a fluorescence microscope. Images were taken using a 20×objective. Viability was quantified according to a ratio of PI (dead cells) and Hoechst (all cells) normalized to control cells.
| Measurement of IL-1β and TNF-α release
NLRP3 inflammasome activation by Aβ was determined by measuring the IL-1β secretion using the mouse IL-1 beta/IL-1F2 DuoSet ELISA kit. To assess the extent of the inflammatory response, tumor necrosis factor alpha (TNF-α) release was determined using the mouse TNF-α DuoSet ELISA kit. Primary microglia cells were treated with 1 ml medium per well in 6-well plates. After the LPS priming and Aβ treatment with relevant controls, the cell culture supernatants were harvested and frozen at −80°C. Supernatants were thawed once and assayed according to the manufacturer's protocol.
The optical density was determined at 450 nm photometrically with a microplate reader (Infinite M200; Tecan). The concentration of cytokine released was quantified using the relevant standard curves.
| Immunocytochemistry
Cells were stained in IbiTreat 8-well µ-slides or 96-well µ-plates. After stimulation with the various NLRP3-inflammasome-inducing reagents and appropriate controls, cells were washed with PBS and fixed in 4% PFA dissolved in PBS for 15 min and permeabilized with 0.1% Triton X-100 prepared in PBS for 10 min. Blocking solution-PBS containing 5% normal goat serum (1:200) was applied for 30 min followed by two washing steps. The primary antibodies rabbit anti-ASC (1:200; clone AL177), rat anti-CD68 (1:1,000; Clone FA-11) and mouse anti-Aβ (3.3 μg/ml; clone 11E12, Dalgediene et al. 2013 ) were added to the blocking solution and incubated overnight. The following secondary antibodies were used, respectively: goat anti-rabbit (1:600), goat antirat (1:600) and goat anti-mouse (1:600). The secondary antibodies were applied for 2 hr followed by two washing steps. Hoechst33342 was used for nuclear staining at 1 μg/mL for 30 min in PBS. ASC speck images were taken using a 60× oil-objective. The uptake of Aβ oligomers and protofibrils was measured by imaging with 40× objective.
CD68 was used as a microglia and lysosomal marker.
| FLICA assay (active caspase-1)
Active caspase-1 was detected using the FLICA assay according to manufacturer's protocol. Briefly, cells were stained in IbiTreat µ-slides with eight wells. FLICA reagent (FAM-YVAD-FMK-caspase-1 inhibitor probe) was added after the 6 hr treatment with Aβ and incubated for 1 hr. Cells were washed three times and stained with Hoechst 33,342 at 1 μg/ml and membrane dye (1:1,000). After washing the cells were fixed with 4% PFA and washed again with PBS. Caspase-1 activation was analysed directly after staining. The signal was visualized by fluorescence microscopy using a 60× oilobjective. FLICA-caspase-1 intensity signal was measured and normalized to cell number. In every experiment, the calculated value of FLICA-caspase-1 intensity was normalized to the value of untreated cells (control).
| Microscopy
All experiments were examined using a Nikon Eclipse Ti fluorescence microscope (Nikon). Acquired images were processed using NISelements 4 (Nikon) and ImageJ (Wayne Rusband; National Institute of Health) by a person who was blind for the experimental conditions.
| Flow cytometry
To evaluate Aβ phagocytosis flow cytometric analysis was performed. Microglia that were incubated with various stimuli were collected by detaching with 0.25% trypsin-EDTA solution for 10 min and the trypsin was then inhibited with DMEM supplemented with 10% FBS and 1% P/S. After washing the cells were fixed with 4% PFA for 10 min and permeabilized with 0.03% Triton X-100 for 5 min.
After washing the cell surface receptors, FcγRIII (CD16) and FcγRII (CD32) were blocked with Fc block (anti-mouse CD16/32) solution.
The cells were incubated with primary antibodies against Aβ (clone 11E12) overnight at 4°C. After washing, the cells were stained with rat anti-mouse CD11b-APC (1:100; clone M1/70) together with the secondary antibodies goat anti-mouse (1:600) for 1 hr at 4°C. After washing, microglia were resuspended in staining solution (2% FBS in PBS). Flow cytometric data was acquired on a BD FACSCanto II flow cytometer (Becton, Dickinson and Company) and analysed using FlowJo software (FlowJo, LLC).
| Immunoblotting
The quantity of cleaved caspase-1 was determined by Western-blot using the Jess fully automated system (ProteinSimple; Bio-Techne) following the suggested protocol of the system. Primary microglia were cultured in 6-well plates and treated at a density of 2 million cells/ml per 9.5 cm 2 growth area. The protein content of the supernatants was concentrated 10× using centrifugal filters with 3 kDa cutoff. The chemiluminescence assay was used following ProteinSimple instructions. Samples were prepared as following:
First, 5× master mix was prepared using reagents provided by Bio-Techne (EZ Standard Pack 1, cat. no.: S-ST01EZ-8). 1/2 10× Sample buffer was mixed with 1/2 400 mM DTT solution; cell culture supernatant was mixed 1-4 with 5× master mix, heated at 95°C for 5 min and stored on ice. Here 12-230 kDa Jess/Wes Separation Module was used and 3 μl of each sample was loaded for 9 s. The incubation time of the primary and the secondary antibodies was 30 min. As a primary antibody, anti-caspase-1 was used at a concentration of 20 μg/ml (1:50 dilution). For the secondary antibody, ready to use HRP-conjugated goat anti-mouse antibody was used. 
| Statistical analysis
| RE SULTS
Aβ aggregates of different size and structure were used to investigate NLRP3 inflammasome activation in primary murine microglia.
Microglial cells were primed with LPS to induce translation of the NLRP3 inflammasome components and subsequently treated with various Aβ aggregates. NLRP3 inflammasome assembly and activation was analysed by detection of cleaved caspase-1, ASC speck F I G U R E 1 Aβ characterization by atomic force microscope and confirmation that Aβ oligomers do not aggregate to fibrils during the cell treatment period. Representative images of Aβ oligomers and protofibrils prepared according to different protocols: (a) Oligomersprepared using Protocol I; mainly 1-5 nm in size. (c) Protofibrils-prepared using Protocol II. (b) and (d) Histograms of height distribution of Aβ particles, n = 3 independent Aβ preparations. After preparation of Aβ oligomers and protofibrils, they were diluted with cell culture medium to 2.5 μM and incubated for 6 hr at 37°C under cell-free conditions. Aβ oligomers and protofibrils dissociated into smaller particles. After additional incubation of protofibrils, a higher fraction of small oligomers, about 1-2 nm in size was detected. Oligomers dissociated into small particles as the scanned surface was fully covered with very small Aβ particles. The scanned size of the images is 1.5 x 1.5 μm. All images are represented in height scale from 0 to 7 nm formation, and IL-β release. Additionally, the NLRP3 inflammasome inhibitor MCC950 was used and nigericin was included as a positive control.
| Characterization of Aβ structure
The morphology of the prepared Aβ structures was revealed by AFM. Oligomers of 1-5 nm in height were observed after preparation according to Protocol I, and in preparation according to Protocol II protofibrils ~5 nm in height were found. To confirm that the oligomers were intact and did not form fibrils during cell culture treatment at 37°C, further analysis was performed. The solution of 2.5 μM Aβ was incubated in cell culture medium for 6 hr at 37°C and 5% CO 2 atmosphere to mimic the culture conditions during microglia treatment.
The morphology of the prepared Aβ species was analysed before and importantly, after an incubation period of 6 hr (Figure 1 ). Aβ aggregates dissociated after dilution from 100 to 2.5 μM and 6 hr incubation at 37°C. It should be noted that Aβ monomers and dimers were observed by AFM in all Aβ preparations analysed. If Aβ aggregates are very large, they overshadow monomers and small oligomers. After the additional incubation step, the mica sheets were prepared in the same way as before, however, the results shown in Figure 1 
| Aβ had no influence on cell viability
Persistent NLRP3 inflammasome activation is often characterized by the induction of an inflammatory pyroptotic cell death. To test whether the Aβ oligomers or protofibrils affected microglial viability over the treatment period of 6 hr, several cytotoxicity assays were performed. Nigericin was used as a positive control.
After treatment with Aβ oligomers and protofibrils, no significant changes in metabolic activity (Figure 2a ) or LDH release (Figure 2b) were found. To detect cell viability changes at an individual single cell level PI and Hoechst nuclear staining was used (Figure 2c and d) .
While occasionally single dead microglia were detectable, no significant effect on cell viability was found in treatment groups when compared with controls. These data indicate the the respective Aβ preparations did not affect microglial viability (pyroptosis) under these experimental conditions.
| Aβ oligomers and protofibrils were phagocytosed at a similar extent by microglia
The uptake of Aβ by microglia was investigated by immunocytochemistry. To detect phagocytosis, it was investigated whether F I G U R E 4 Aβ oligomers and protofibrils induce interleukin-1β (IL-1β) release in murine microglia. Microglia were primed with 50 ng/ ml lipopolysaccharide (LPS) and treated with Aβ oligomers or protofibrils for 6 hr at 2.5 μM. MCC950 (1 μM) was added 20 min before Aβ treatment. Nigericin (10 μM) was used as a positive control. Supernatants were collected and analysed by ELISA, for (a) IL-1β release, n = 10 independent cell culture preparations and (b) Tumor necrosis factor alpha release, n = 6 independent cell culture preparations. Con O.oligomer control, Con P.-protofibrils control. Data are represented using box plots, **p < .01, ****p < .0001, one-way ANOVA followed by Bonferroni's multiple comparison test Additionally, Aβ oligomer or protofibril uptake was analysed by FACS ( Figure 3c and d) . Again, both Aβ oligomers and protofibrils were phagocytosed to a similar extent by microglia. However, a small population of cells were highly immunopositive for Aβ (Aβ high) after treatment with both oligomers and protofibrils (Figure 3c ), suggesting a heterogenous phagocytic capacity across the microglial cell population.
| Both Aβ oligomers and protofibrils induced IL-1β secretion
Next, the induction of pro-inflammatory cytokines in microglia was investigated. Both Aβ oligomers and protofibrils induced a significant increase in IL-1β release (Figure 4a ). This IL-1β release was completely inhibited by co-incubation with the specific NLRP3 inflammasome inhibitor MCC950. The secretion of another pro-inflammatory cytokine, TNF-α, was also measured (Figure 4b) , however, no significant changes in TNF-α release were detected after Aβ treatment in comparison to control cells. These results show that Aβ oligomers and protofibrils activate the microglial NLRP3 inflammasome, resulting in IL-1β production.
| Aβ-Induced activation of caspase-1
To investigate whether the Aβ-induced IL-1β release occurred through activation of caspase-1, cleavage of caspase-1 to its p20 kDa subunit was analysed. A significant increase in cleaved caspase-1 secretion was detected after co-culture with Aβ oligomers or protofibrils ( Figure 5 ). These results were confirmed using a fluorescent cell-permeable probe (FLICA) that covalently binds only to activated caspase-1 ( Figure 6 ). Aβ oligomers or protofibrils significantly induced FLICA + caspase-1 activation in microglia cells.
These data demonstrate that the IL-1β release induced by Aβ oligomers and protofibrils was mediated by the activation and cleavage of caspase-1.
| Both Aβ oligomers and protofibrils induced ASC speck formation
Oligomerization of the inflammasome adaptor protein ASC into a large 'ASC speck' complex is an essential inflammasome activation step, which is a platform for pro-caspase-1 recruitment and activation. To test whether Aβ oligomers or protofibrils induced ASC treatment. ASC specks were found inside the cells (Figure 7 ). This suggests that these Aβ preparations can act as potent inducers of ASC speck formation.
| D ISCUSS I ON
Here we demonstrate that soluble, low molecular weight Aβ oligomers and protofibrils can activate the NLRP3 inflammasome in microglia without inducing a pyroptotic inflammatory cell death during the observation period. Importantly, the morphology of the oligomer and protofibril preparations used for cell stimulation were not altered during the incubation period as evidenced by AFM, therefore the NLRP3 inflammasome was indeed activated by small, soluble Aβ oligomers with a maximum size of 5 nm.
There are several studies that have shown both natural and synthetic Aβ oligomers exert neurotoxic effects in vitro (Yang et al., 2017; Yasumoto et al., 2019) . However, some controversy exists on the particular morphology and length that accounts for these observations.
Some studies have shown that Aβ42 forms oligomers faster in comparison with other Aβ species and the subsequently formed Aβ oligomers had significantly higher cytotoxicity for neurons (Ferrera et al., 2014; Li et al., 2018) . In addition, primary microglia cells internalized Aβ42 protofibrils with a higher preference than Aβ42 monomers (Gouwens, Makoni, Rogers, & Nichols, 2016) . In this study, we showed that small Aβ oligomers and protofibrils were able to activate murine microglia cells without affecting their viability. Together this suggests that the respective soluble Aβ species are able to induce an innate immune response prior to the deposition of Aβ in the so-called neuritic plaques.
We found that microglia phagocytosed both the Aβ oligomers and protofibrils to the same extent. Using FACS analysis, we could identify cells with a significantly higher Aβ content suggesting that some microglia have a higher phagocytotic activity than others. The reason for this difference in Aβ uptake is not yet known. It is important to note that even this phagocytic effect was independent of the Aβ size. In turn, an early compromise in the microglial phagocytic capacity may lead to an unfavourable increase of these Aβ species in the CNS, which could then aggregate further into dense Aβ-containing plaques over time.
Next, we investigated whether these soluble Aβ species were able to activate the NLRP3 inflammasome, a key element of innate immune activation in myeloid cells. One of the hallmarks of the NLRP3 inflammasome activation is the caspase-1 activity, which cleaves pro-IL-1β to the mature and active IL-1β. It is well known that fibrillary Aβ can act as a damage-associated molecular pattern and activate the NLRP3 inflammasome (Halle et al., 2008; Sheedy et al., 2013) , however, whether soluble Aβ oligomers and protofibrils share this immunoactive property has not yet been demonstrated. Here, we found that small Aβ oligomers and protofibrils induce caspase-1 activation and subsequent IL-1β release, which was blocked by MCC950, a known NLRP3 inflammasome inhibitor (Coll et al., 2015) .
F I G U R E 7
Aβ induced apoptosis-associated speck-like protein containing a CARD (ASC) speck formation. Microglia were primed with 50 ng/ml lipopolysaccharide and treated with Aβ oligomers or protofibrils for 6 hr at 2.5 μM concentration. Nigericin (10 μM) was used as a positive control. Cells were immunostained with anti-Aβ (red), anti-ASC (green) and nuclear stain Hoechst (blue). (a) Representative images of one experiment. White arrows show ASC specks. The images were taken using 60x-oil objective. The scale bars indicate 40 μm.
(b) Quantification of Aβ mean intensity per cell. Cells with and without ASC specks were quantified. In oligomers treatment, 59 cells were counted and 9 of these had incorporated ASC specks (15.2%); in protofibrils -6 cells out of the 57 counted had ASC specks (10.5%). There was no significant difference in Aβ uptake comparing ASC Formation of the NLRP3 inflammasome and a subsequent caspase-1 activation also leads to nitric oxide formation and TNF-α release, which occurs downstream of IL-1β release (Halle et al., 2008; Heneka, 2017) . We could not detect any change in TNF-α release induced by Aβ oligomers or protofibrils. This is likely due to a difference in the timing of the experiments, as we assessed cytokine release after 6 hr, whereas other studies found that TNF-α was present 24 hr after Aβ treatment in primed cells. In addition, LPS priming already induced TNF-α release, which may have led to a ceiling effect with maximal TNF-α that could not be further augmented by subsequent exposure to Aβ oligomers or protofibrils within our 6 hr assay. However, recent studies revealed that Aβ protofibrils but not monomers are robust stimulators of TNFα release (Gouwens et al., 2016; Paranjape, Gouwens, Osborn, & Nichols, 2012) .
As mentioned above, we found that Aβ oligomers and protofibrils induced ASC speck formation, which is an important step in NLRP3 inflammasome activation as the ASC complex is a platform for procaspase-1 recruitment and activation. ASC speck formation plays an important role in seeding for Aβ pathology where microglial-released ASC specks can bind to Aβ thereby increasing the peptides propensity to aggregate. ASC also had a key role in mediating APP/ PS1 brain lysate-induced Aβ seeding, together suggesting that microglial release of ASC specks is one of the initiating mechanisms for Aβ deposition .
This study shows that soluble Aβ oligomers and protofibrils are phagocytosed by microglia and can activate all important components of the NLRP3 inflammasome, including ASC speck formation and IL-1β release. This early neuroinflammatory event can trigger further neuropathological changes and enhance progression or acceleration to AD-associated dementia.
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